The estimated Net Worth of Brad Vale is at least $1.16 Million dollars as of 1 March 2021. Brad Vale owns over 5,303 units of Nevro Corp stock worth over $33,116 and over the last 10 years he sold NVRO stock worth over $890,056. In addition, he makes $237,955 as Independent Director at Nevro Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Brad Vale NVRO stock SEC Form 4 insiders trading
Brad has made over 2 trades of the Nevro Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,303 units of NVRO stock worth $890,056 on 1 March 2021.
The largest trade he's ever made was selling 5,303 units of Nevro Corp stock on 1 March 2021 worth over $890,056. On average, Brad trades about 456 units every 121 days since 2015. As of 1 March 2021 he still owns at least 7,031 units of Nevro Corp stock.
You can see the complete history of Brad Vale stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brad Vale biography
Dr. Brad H. Vale, Ph.D. D.V.M. is Independent Director of the Company. Dr. Vale was Head of Johnson & Johnson Development Company (“JJDC”), from January 2012 to March 2015. Dr. Vale joined JJDC in March 1992 and was appointed to the position of Vice President, Head of Venture Investments in April 2008. From September 1989 to March 1992, Dr. Vale supported Johnson & Johnson’s medical device businesses at the Corporate Office of Science and Technology as an Executive Director. From 1982 to 1989, he was at Ethicon, Inc., a Johnson & Johnson subsidiary, working on preclinical studies, new business development, and a coronary artery bypass graft internal venture. Dr. Vale currently serves or has served on the board of directors of several private companies, including Neuropace, Inc., Northstar Neuroscience, Inc., CVRx, Inc. and ShiraTronics, Inc. Dr. Vale holds a Ph.D. from Iowa State University, a D.V.M. from Washington State University and a B.S. in Chemistry and Biology from Beloit College. Vale is qualified to serve on our Board due to his investment experience and strategic leadership in the life sciences industry.
What is the salary of Brad Vale?
As the Independent Director of Nevro Corp, the total compensation of Brad Vale at Nevro Corp is $237,955. There are 17 executives at Nevro Corp getting paid more, with D.Keith Grossman having the highest compensation of $13,877,700.
How old is Brad Vale?
Brad Vale is 67, he's been the Independent Director of Nevro Corp since 2015. There are 1 older and 23 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
What's Brad Vale's mailing address?
Brad's mailing address filed with the SEC is C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Insiders trading at Nevro Corp
Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo, and & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.
What does Nevro Corp do?
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
What does Nevro Corp's logo look like?
Complete history of Brad Vale stock trades at Nevro Corp
Nevro Corp executives and stock owners
Nevro Corp executives and other stock owners filed with the SEC include:
-
D.Keith Grossman,
Chairman of the Board, President, Chief Executive Officer -
Niamh Pellegrini,
Chief Commercial Officer -
Michael Carter,
Vice President - Global Sales -
Christopher Christoforou,
Vice President - Research and Development -
D. Keith Grossman,
Chairman, CEO & Pres -
Patrick Schmitz,
Vice President - Operations -
Kashif Rashid,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Andrew H. Galligan,
Exec. Officer -
Kashif Rashid,
Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Roderick H. MacLeod,
Chief Financial Officer -
Elizabeth Weatherman,
Independent Director -
Kevin O'Boyle,
Independent Director -
Karen Prange,
Independent Director -
Michael DeMane,
Lead Independent Director -
Wilfred Jaeger,
Independent Director -
Shawn McCormick,
Independent Director -
Frank Fischer,
Independent Director -
Brad Vale,
Independent Director -
David Caraway,
Chief Medical Officer -
Donald Middlebrook,
Vice President - Clinical, Regulatory and Quality -
Juliet Cunningham,
Vice President - Investor Relations -
Lori Ciano,
Chief Human Resource Officer -
Roderick MacLeod,
Chief Financial Officer -
Dr. David Caraway,
Chief Medical Officer -
Lori M. Ciano,
Chief HR Officer -
Patrick Schmitz,
VP of Operations -
Jon R. Shear,
VP of Corp. Devel. -
Michael Collier Carter,
VP of Global Sales -
Julie D. Dewey,
Chief Corp. Communications & Investor Relations Officer -
Sridhar Kosaraju,
-
James Alecxih,
Vice President, Sales -
Lisa D Earnhardt,
Director -
Andre Walker,
Senior VP,Research&Development -
Ali Behbahani,
Director -
Kevin R Thornal,
President & CEO -
Rami Elghandour,
President -
Michael Enxing,
VP of Sales & Marketing -
Arch Management Iv, L.L.C.T...,
-
City Capital Llc Bay City C...,
-
Holdings A/S Novo,
10% owner -
Partners Ii Lp Amv,
-
City Capital Llc Bay City C...,
-
Nathan B Pliam,
Director -
& Johnson Johnson & Johnson...,
-
Balakrishnan Shankar,
VP, Operations -
Andrew H Galligan,
Chief Financial Officer -
Doug Alleavitch,
VP, Quality -
Kirt P Karros,
-
Christofer Christoforou,
SVP, Chief Operating Officer -
Greg Siller,
SVP & Chief Commercial Officer -
Richard B. Carter,
Chief Accounting Officer -
Susan E Siegel,